NCT Number: NCT02183103
Influence of a High Fat Breakfast in the Pharmacokinetics of UH-AC62MU in Healthy Subjects
Influence of a high fat breakfast in the pharmacokinetic profile of the 7.5 mg meloxicam rapid releases tablet
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–50 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy subjects as determined by results of screening
- Written informed consent according good clinical practice (GCP) and local legislation
- Age >=18 and <=50 years
- Broca >= -20% and <= +20%
Exclusion criteria
- Any finding of the medical examination (blood pressure, pulse rate and electrocardiogram (ECG)) deviating from the normal and of clinical relevance
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorder
- Surgery of gastro-intestinal tract (except appendectomy)
- Disease of central nervous system (such as epilepsy) or psychiatric disorders or neurological disorder
- History of orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which deemed relevant to the trial as judged by the investigator
- Intake of drugs with a long half-life ( >24h) (<=1month prior to administration)
- Use of any drugs which might influence the results of the trial (<=10 days prior to administration or during the trial)
- Participation in another trial with an investigational drug (<= 2 months prior to administration or during the trial)
- Smokers ( >10 cigarettes or >3 cigars or >3 pipes/day)
- Inability to refrain from smoking on trial days
- Alcohol abuse (>60g/day)
- Drug abuse
- Blood donation (<= 1 month prior to administration or during the trial)
- Excessive physical activities (<= 5 days prior to administration or during the trial)
- Any laboratory value outside the reference range of clinical relevance
- History of hemorrhagic diatheses
- History of gastro-intestinal ulcer, perforation or bleeding
- History of bronchial asthma
For female:
- Pregnancy
- Positive pregnancy test
- No adequate contraception e.g. sterilization, intrauterine device (IUD), oral contraceptives
- Inability to maintain this adequate contraception during the whole study period
- Lactation period
Treatment and study plan
Primary outcomes
-
Maximum measured concentration of the analyte in plasma (Cmax)
Time frame: predose and up to 96 hours after drug administration
-
Area under the concentration-time curve of the analyte in plasma from time zero to infinity (AUC 0-infinity)
Time frame: predose and up to 96 hours after drug administration
Secondary outcomes
-
Time to achieve Cmax (tmax)
Time frame: predose and up to 96 hours after drug administration
-
Area under the concentration-time curve of the analyte in plasma from time zero to t (AUC 0-t)
Time frame: predose and up to 96 hours after drug administration
-
Terminal rate constant in plasma (λz)
Time frame: predose and up to 96 hours after drug administration
-
Terminal half-life of the analyte in plasma (t1/2)
Time frame: predose and up to 96 hours after drug administration
-
Mean residence time of the analyte total (MRT tot)
Time frame: predose and up to 96 hours after drug administration
-
Apparent clearance of the analyte in plasma following extravascular administration (CL/F)
Time frame: predose and up to 96 hours after drug administration
-
Apparent volume of distribution during the terminal phase λz following extravascular administration (Vz/F)
Time frame: predose and up to 96 hours after drug administration
-
Number of patients with abnormal changes in laboratory values
Time frame: Baseline, 96 hours after drug administration
-
Number of Participants with Adverse Events
Time frame: Up to day 5 after last drug administration
-
Number of patients with abnormal changes from baseline in ECG
Time frame: Baseline, day 5 after last drug administration
-
Number of patients with abnormal changes from baseline in physical examination
Time frame: Baseline, day 5 after last drug administration
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
Influence of a High Fat Breakfast in the Pharmacokinetics of UH-AC62MU (Rapid Release Tablet) Given as an Oral Single Dose of 7.5 mg in Healthy Subjects (Two Way, Crossover, Randomized, Open)
Important dates
- Study start
- 1999
- Primary completion
- 1999
- First posted
- Jul 8, 2014
- Registry last updated
- Jul 8, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Tumor-Derived FGF19
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsAI Chatbot for HPV Vaccine Literacy Among Caregivers in Japan
NCT06702423
Healthy
London, United Kingdom
View Trial DetailsValidation of the Masimo Irregular Heartbeat Detection Algorithm in Participants Without Cardiovascular Disease
NCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNormative Value for Navicular Drop Test in Older Adults
NCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details